UCB: Will Cimzia Be Enough?
Executive Summary
Cimzia's success is critical for UCB--not least to justify its $2.7 billion Celltech acquisition. But Cimzia will also be a test-case for whether mid-cap pharma can compete in biologics, particularly as the new Medicare program rolls out.
You may also be interested in...
Best of the Blog: IN VIVO, May/June 2009
Our favorite blog posts related to stories not covered elsewhere in this month's IN VIVO.
Best of the Blog: IN VIVO, May/June 2009
Our favorite blog posts related to stories not covered elsewhere in this month's IN VIVO.
Can Amgen Find a New Engine?
Amgen's string of misfortunes has highlighted the group's need to find an alternative growth engine--one which will, necessarily, look very different from the current anemia franchise. The biotech is leaning too heavily on osteoporosis and cancer candidate denosumab.